Prognostic impact of chemotherapy in primary hepatic diffuse large B-cell lymphoma:a SEER-based machine learning analysis
10.7659/j.issn.1005-6947.230402
- VernacularTitle:化疗对原发性肝脏弥漫大B细胞淋巴瘤预后的影响:基于SEER数据库与机器学习的分析
- Author:
Kun HUANG
1
;
Wen WANG
;
Ting YANG
;
Yunsheng HE
;
Jun FENG
Author Information
1. 四川省绵阳市中医医院 普通外科,四川 绵阳 621000
- Publication Type:Journal Article
- Keywords:
Liver Neoplasms;
Lymphoma,Large B-Cell,Diffuse;
Drug Therapy;
Prognosis;
SEER Program
- From:
Chinese Journal of General Surgery
2025;34(7):1401-1409
- CountryChina
- Language:Chinese
-
Abstract:
Background and Aims:Primary hepatic diffuse large B-cell lymphoma(DLBCL)is rare and carries a poor prognosis,with no large-scale evidence supporting the value of chemotherapy.This study used real-world,large-sample data from the SEER database to evaluate the prognostic impact of chemotherapy in patients with primary hepatic DLBCL.Methods:Clinical data of patients pathologically diagnosed with primary hepatic DLBCL between 2000 and 2019 were extracted from the SEER database and grouped according to whether they received chemotherapy.Kaplan-Meier survival analysis,Cox proportional hazards models,and random survival forest models were employed to identify factors influencing overall survival(OS)and cancer-specific survival(CSS),and subgroup analyses were performed.Results:A total of 594 patients were included,with a median age of 66 years;435(73.2%)received chemotherapy.After a median follow-up of 17.5 months,the median OS was 81(7-173)months in the chemotherapy group versus 11(2-171)months in the non-chemotherapy group.The OS and CSS rates in the chemotherapy group were significantly higher than those in the non-chemotherapy group(67.99%vs.47.77%;71.03%vs.52.87%,both P<0.05).Multivariate analysis showed that chemotherapy was an independent protective factor for OS(HR=0.39,95%CI=0.31-0.48)and CSS(HR=0.37,95%CI=0.29-0.48).In the random survival forest model,chemotherapy ranked highest in variable importance.Subgroup analyses produced consistent results.Conclusion:Chemotherapy is an independent prognostic factor for patients with primary hepatic DLBCL and can significantly improve survival.The R-CHOP regimen may be the preferred therapeutic option.
